We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Vircell S.L.

Vircell is a biotechnology company specializing in the development and production of ready-to-use reagents for the di... read more Featured Products: More products

Download Mobile App




Commercial Kits Evaluated for Mediterranean Visceral Leishmaniasis

By LabMedica International staff writers
Posted on 16 Apr 2020
Human visceral leishmaniasis (VL) is a neglected disease endemic in the Mediterranean region, caused by Leishmania infantum. More...
Accurate VL diagnosis is critical for rapid and correct patient management. Dogs are the main reservoir of L. infantum parasites that are transmitted to humans by the bite of infected phlebotomine sand flies.

Parasite detection by microscopic examination of bone marrow aspirates is the gold standard method, but lacks sensitivity and requires invasive procedures. The culture of parasites isolated from patients might improve the diagnostic sensitivity. Various methods are used for VL serodiagnosis and molecular tests have been employed.

A team of scientists at the Université de Montpellier (Montpellier, France) and their international colleagues tested serum samples from 319 patients living in France, Tunisia or Morocco. The population of 181 with proven VL included 65 immunocompromised patients.

The serum samples were tested with two immunochromatographic tests (ICT): IT LEISH and TruQuick LEISH IgG/IgM (Meridianbioscience, Cincinnati, OH, USA) and four enzyme-linked immunosorbent assay (ELISA) reagents: NovaLisa Leishmania infantum IgG (NovaTec Immundiagnostica GmbH, Dietzenbach, Germany); Bordier Leishmania infantum (Bordier Affinity Products SA, Crissier, Switzerland); Ridascreen Leishmania IgG (R-Biopharm AG, Darmstadt, Germany); and Vircell Leishmania (Vircell, Granada, Spain).

The team reported that significantly higher percentages of false-negative results were obtained with all assays in immunocompromised patients, compared with the immunocompetent population. In the whole population, sensitivity and specificity ranged from 80.7% to 93.9% and from 95.7% to 100%, respectively. The maximum accuracy was observed with the Bordier and Vircell ELISA kits (96.2%), and the lowest accuracy with Ridascreen reagent (88.7%). New thresholds of positivity are proposed for the Bordier, Vircell and NovaLisa ELISA kits to achieve 95% sensitivity with the highest possible specificity. Western blot (WB), used as a confirmation method, showed 100% sensitivity and identified 10.1% of asymptomatic carriers among the control population from the South of France.

The authors concluded that the Vircell and Bordier ELISA kits displayed significantly higher accuracy rates in the whole population than the other tests. For field studies, the TruQuick ICT is the most suitable with satisfactory performances. In immunocompromised patients, the index values of all ELISA reagents were significantly lower than in the immunocompetent population and false-negative results were more frequent. The study was published on March 25, 2020 in the journal PLOS Neglected Tropical Diseases.



New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The Co-Dx PCR platform combines real-time PCR quality with a lower-cost instrument and consumable model to facilitate deployment near the patient (Photo courtesy of Co-Diagnostics, Inc.)

Point-of-Care Multiplex PCR Test Submitted to FDA for Flu A/B and RSV Detection

Co-Diagnostics, Inc. (Co-Dx; Salt Lake City, UT, USA) has submitted the Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test for use on the Co-Dx PCR Pro instrument through a Dual 510(k) premarket... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.